World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
89
Citations
25596
World Ranking
1126
National Ranking
598

Medicine

D-Index
89
Citations
25596
World Ranking
12802
National Ranking
6541

Pedro A. Piedra publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pedro A. Piedra sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 302 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Pedro A. Piedra D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pedro A. Piedra sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 89 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Pedro A. Piedra is affiliated with Baylor College of Medicine in the United States. The primary fields of study for this researcher are in Medicine, with extensive work specifically in Epidemiology, Infectious Diseases, and Pulmonary and Respiratory Medicine. Additional subfields include Animal Science and Zoology as well as Surgery.

Their research focuses significantly on respiratory viral infections and related topics, including:

  • Respiratory viral infections research
  • SARS-CoV-2 and COVID-19 research
  • Viral gastroenteritis research and epidemiology
  • Influenza virus research studies
  • SARS-CoV-2 detection and testing
  • Neonatal respiratory health research
  • Pneumonia and respiratory infections

Pedro A. Piedra has contributed to multiple recent papers in notable medical journals. Some of the key publications include:

  • "Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine," 2020, published in New England Journal of Medicine
  • "SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice," 2021, published in Nature Communications
  • "Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants," 2020, published in New England Journal of Medicine
  • "Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016," 2020, published in PEDIATRICS
  • "NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge," 2020, published in Vaccine

The researcher frequently publishes in venues such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Open Forum Infectious Diseases
  • The Journal of Infectious Diseases
  • Nature Communications
  • Vaccine

Pedro A. Piedra has collaborated extensively with other researchers. Frequent co-authors include:

  • Vasanthi Avadhanula
  • Geoffrey A. Weinberg
  • Rangaraj Selvarangan
  • Natasha Halasa
  • Janet A. Englund

Best Publications

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

    Cheryl Keech;Gary Albert;Iksung Cho;Andreana Robertson

  • The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

    Robert B. Belshe;Paul M. Mendelman;John Treanor;James King

  • Impact of respiratory virus infections on persons with chronic underlying conditions.

    W P Glezen;S B Greenberg;R L Atmar;P A Piedra

  • Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

    Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Iksung Cho

  • Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

    Núria Morral;Wanda O’Neal;Karen Rice;Michele Leland

  • Prospective Multicenter Study of Viral Etiology and Hospital Length of Stay in Children With Severe Bronchiolitis

    Jonathan M. Mansbach;Pedro A. Piedra;Stephen J. Teach;Ashley F. Sullivan

  • Correlates of Immune Protection Induced by Live, Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine

    Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Harshvardhan B. Mehta

  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.

    Jing Hui Tian;Nita Patel;Robert Haupt;Haixia Zhou

  • The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

    Natalie I Mazur;Deborah Higgins;Marta C Nunes;José A Melero

  • Circulation Patterns of Group A and B Human Respiratory Syncytial Virus Genotypes in 5 Communities in North America

    Teresa C. T. Peret;Caroline B. Hall;Gregory W. Hammond;Pedro A. Piedra

  • Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates

    Suzanne E. Ohmit;Mark G. Thompson;Joshua G. Petrie;Swathi N. Thaker

  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

    Shabir A Madhi;Fernando P Polack;Pedro A Piedra;Flor M Munoz

  • Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.

    Pedro A. Piedra;Manjusha J. Gaglani;Claudia A. Kozinetz;Gayla Herschler

  • Influenza virus infections in infants.

    W. Glezen;Larry Taber;Arthur Frank;William Gruber

  • Influenza Vaccine Effectiveness in the United States During 2012–2013: Variable Protection by Age and Virus Type

    Huong Q. McLean;Mark G. Thompson;Maria E. Sundaram;Burney A. Kieke

  • Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector

    In-Hoo Kim;Alicja Józkowicz;Pedro A. Piedra;Kazuhiro Oka

  • Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.

    Flor M Munoz;Pedro A Piedra;W Paul Glezen

  • Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

    Laurent Detalle;Thomas Stohr;Concepción Palomo;Pedro A. Piedra

  • Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

    Pedro A. Piedra;Alan M. Jewell;Stanley G. Cron;Robert L. Atmar

  • Disseminated Adenovirus Disease in Immunocompromised and Immunocompetent Children

    Flor M. Munoz;Pedro A. Piedra;Gail J. Demmler

  • Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis

    Peter W. Hiatt;Susan C. Grace;Claudia A. Kozinetz;Soufia Helioui Raboudi

Frequent Co-Authors

Carlos A. Camargo
Carlos A. Camargo Harvard University
Manjusha Gaglani
Manjusha Gaglani Baylor College of Medicine
Brian E. Gilbert
Brian E. Gilbert Baylor College of Medicine
Joseph F. Petrosino
Joseph F. Petrosino Baylor College of Medicine
Janet A. Englund
Janet A. Englund Seattle Children's Hospital
L F Fries
L F Fries Novavax (United States)
James E. Gern
James E. Gern University of Wisconsin–Madison
Nadim J. Ajami
Nadim J. Ajami The University of Texas MD Anderson Cancer Center
Alicia M. Fry
Alicia M. Fry Emory University
Chad A. Shaw
Chad A. Shaw Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing immunology opens doors to various health science careers, many of which can be enhanced or supported through online degree programs. For those interested in nursing as a pathway, several online options offer flexible entry points. Exploring the easiest absn to get into can help students transition quickly into the nursing field while balancing other commitments.

For prospective nurses seeking foundational qualifications, the lpn programs easy to get into provide accessible routes with shorter timelines. These programs often serve as a stepping stone toward advanced clinical roles aligned with immunology-related healthcare specialties.

Advancing further, those looking to specialize clinically in immunology-related patient care might consider programs listed among the easiest online nurse practitioner programs. These degrees prepare nurses for autonomous practice, often emphasizing advanced pathophysiology and immunological knowledge essential for treating immune-related conditions.

Finally, for professionals focused on mental health’s intersection with immune function, best online pmhnp programs offer exceptional clinical placement opportunities. These programs support the development of expertise critical to addressing psychoneuroimmunology in patient care.

Best Scientists Citing Pedro A. Piedra

Trending Scientists

Recently Published Articles